(Q35988000)

11 August 2017

1 reference

title

New insights into the pathophysiology of diabetic nephropathy: from haemodynamics to molecular pathology (English)

1 reference

11 August 2017

1 reference

1 reference

1 reference

Wolf G

1

1 reference

11 August 2017

1 December 2004

1 reference

European Journal of Clinical Investigation

11 August 2017

1 reference

11 August 2017

34

1 reference

11 August 2017

785-796

1 reference

11 August 2017

12

1 reference

Clinical practice. Nephropathy in patients with type 2 diabetes

11 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2004.01429.X

Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2004.01429.X

Progression, remission, regression of chronic renal diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2004.01429.X

Involvement of transforming growth factor-beta in regulation of calcium transients in diabetic vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2004.01429.X

Molecular mechanisms of diabetic renal hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2004.01429.X

High glucose-induced hypertrophy of mesangial cells requires p27(Kip1), an inhibitor of cyclin-dependent kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2004.01429.X

Biochemistry and molecular cell biology of diabetic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2004.01429.X

Effect of high glucose on gene expression in mesangial cells: upregulation of the thiol pathway is an adaptational response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2004.01429.X

Advanced glycation end-products: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2004.01429.X

Structural and functional changes of laminin and type IV collagen after nonenzymatic glycation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2004.01429.X

Advanced glycation end products induce tubular epithelial-myofibroblast transition through the RAGE-ERK1/2 MAP kinase signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2004.01429.X

Putative pathophysiological role of growth factors and cytokines in experimental diabetic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2004.01429.X

Role of growth factors in the development of diabetic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2004.01429.X

Glucose stimulation of transforming growth factor-beta bioactivity in mesangial cells is mediated by thrombospondin-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2004.01429.X

Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2004.01429.X

Blockade of maitotoxin-induced endothelial cell lysis by glycine and L-alanine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2004.01429.X

Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2004.01429.X

Podocyte foot process broadening in experimental diabetic nephropathy: amelioration with renin-angiotensin blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2004.01429.X

ACE-inhibitors but not endothelin receptor blockers prevent podocyte loss in early diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2004.01429.X

Expression of the slit-diaphragm protein, nephrin, in experimental diabetic nephropathy: differing effects of anti-proteinuric therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2004.01429.X

Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2004.01429.X

Transforming growth factor-beta1 is up-regulated by podocytes in response to excess intraglomerular passage of proteins: a central pathway in progressive glomerulosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2004.01429.X

Angiotensin II activates nuclear transcription factor-kappaB through AT1 and AT2 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2004.01429.X

Effectiveness of aldosterone blockade in patients with diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2004.01429.X

Reversal of lesions of diabetic nephropathy after pancreas transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2004.01429.X

Regression of microalbuminuria in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2004.01429.X

10.1111/J.1365-2362.2004.01429.X

21 January 2018

Identifiers

DOI

1 reference

11 August 2017

1 reference

PubMed ID

15606719